Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Haemonetics (HAE) EPS (Basic) (2016 - 2025)

Haemonetics has reported EPS (Basic) over the past 17 years, most recently at $0.96 for Q4 2025.

  • Quarterly results put EPS (Basic) at $0.96 for Q4 2025, up 28.0% from a year ago — trailing twelve months through Dec 2025 was $3.65 (up 42.58% YoY), and the annual figure for FY2025 was $3.33, up 43.53%.
  • EPS (Basic) for Q4 2025 was $0.96 at Haemonetics, up from $0.81 in the prior quarter.
  • Over the last five years, EPS (Basic) for HAE hit a ceiling of $1.17 in Q1 2025 and a floor of -$0.22 in Q2 2021.
  • Median EPS (Basic) over the past 5 years was $0.64 (2022), compared with a mean of $0.55.
  • Biggest five-year swings in EPS (Basic): tumbled 162.86% in 2021 and later soared 533.33% in 2022.
  • Haemonetics' EPS (Basic) stood at $0.29 in 2021, then skyrocketed by 124.14% to $0.65 in 2022, then dropped by 4.62% to $0.62 in 2023, then grew by 20.97% to $0.75 in 2024, then increased by 28.0% to $0.96 in 2025.
  • The last three reported values for EPS (Basic) were $0.96 (Q4 2025), $0.81 (Q3 2025), and $0.71 (Q2 2025) per Business Quant data.